#Germany #Berlin #Lutetium-177 #Eckert Ziegler #AtomVie

Eckert & Ziegler and AtomVie Join Forces for Lutetium-177 Supply

On March 20, 2025, Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. made headlines by signing a significant global supply agreement. This collaboration is set to reshape the landscape of radiopharmaceutical development, particularly in the use of Lutetium-177 chloride, commonly known in the industry as a high-quality non-carrier added product.

A Strategic Partnership

The partnership between these two companies is noteworthy not only for the quality of the product involved but also for the implications it carries for the pharmaceutical sector. Under the terms of the agreement, Eckert & Ziegler will supply Theralugand®, their specialized Lutetium-177 chloride, to bolster AtomVie’s Contract Development and Manufacturing Organization (CDMO) activities related to the manufacturing of radiopharmaceuticals.

This supply agreement covers every stage of development, from early to late-stage processes, thus enabling AtomVie to facilitate a variety of global programs. It ensures that AtomVie has reliable access to Lutetium-177, which is critical for their operations aimed at further developing radiopharmaceuticals within their manufacturing facility.

Flexibility and Responsiveness

The agreement’s inherent flexibility is a significant advantage, allowing AtomVie to respond promptly to the evolving needs of pharmaceutical partners. This responsiveness is crucial, especially in the complex landscape of radiopharmaceutical development and commercialization, where regulatory requirements can vary dramatically across different regions of the world.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, expressed his excitement about the partnership. He stated, "We are happy to support AtomVie in advancing global radiopharmaceutical development programs with Theralugand®. By providing our high-quality radionuclides, we vitally contribute to the further development of therapeutic approaches in nuclear medicine."

Bruno Paquin, the CEO of AtomVie, echoed this sentiment, highlighting the strategic importance of the collaboration. He noted, "Partnering with Eckert & Ziegler is a significant step in ensuring that our global partners developing Lutetium-177 based radiopharmaceuticals have the support they need. With our new facility set to open later this year, this collaboration enhances our ability to provide reliable, high-quality manufacturing services. Together with our partners, we look forward to further advancing innovation and transforming patients' lives."

About the Companies

Eckert & Ziegler

Eckert & Ziegler SE stands as a leading specialist in the isotope-related components for nuclear medicine and radiation therapy. With a workforce of over 1,000 employees, the company provides an extensive range of services and products tailored for the radiopharmaceutical industry. Their offerings span from initial development phases to contract manufacturing and beyond.

The firm’s shares are publicly traded under ISIN DE0005659700, listed on the TecDAX index of Deutsche Börse, symbolizing its standing within the broader market. Their commitment to saving lives through innovative isotopic solutions underscores their mission in the industry.

AtomVie Global Radiopharma

AtomVie Global Radiopharma Inc. has positioned itself as a premier CDMO, excelling in GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. The company is not only equipped with advanced scientific and technical expertise but is also well-versed in regulatory, quality, and logistical aspects that are essential for developing radiopharmaceuticals.

With ongoing studies in more than 25 countries, AtomVie is keen to leverage this partnership to enhance their product offerings and ensure robust support for their international clientele.

In conclusion, the collaboration between Eckert & Ziegler and AtomVie signifies a powerful alliance within the dynamics of nuclear medicine and radiopharmaceuticals, setting the stage for groundbreaking advancements in the field.